Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Capital Expenditures of $3.8 million for Q1 2026, up 1574.71% quarter-over-quarter from -$261000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Capital Expenditures data on file, last reported at $3.8 million in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $3.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 290.59% YoY), and the FY2025 annual result was $467000.0, down 68.06% from the prior year.
- Capital Expenditures climbed to $3.8 million in Q1 2026 per MDGL's latest filing, from -$261000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.8 million in Q1 2026 and troughed at -$488000.0 in Q3 2024.
- A 5-year average of $498266.7 and a median of $103000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 5050.0% in 2022, then slumped 243.95% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $29000.0 in 2022, then surged by 3472.41% to $1.0 million in 2023, then soared by 41.12% to $1.5 million in 2024, then sank by 117.85% to -$261000.0 in 2025, then soared by 1574.71% to $3.8 million in 2026.
- Business Quant data shows MDGL's Capital Expenditures at $3.8 million in Q1 2026, -$261000.0 in Q4 2025, and $728000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.85 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | -261,000.00 |
| Dec 31, 2025 | -261,000.00 |
| Sep 30, 2025 | 728,000.00 |
| Sep 30, 2025 | 728,000.00 |
| Dec 31, 2024 | 1.46 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | -488,000.00 |
| Sep 30, 2024 | -488,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 339,000.00 |
| Sep 30, 2023 | 339,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Jun 30, 2023 | 69,000.00 |